Detalhe da pesquisa
1.
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
N Engl J Med
; 386(7): 617-628, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34898139
2.
Lack of IFN-γ Receptor Signaling Inhibits Graft-versus-Host Disease by Potentiating Regulatory T Cell Expansion and Conversion.
J Immunol
; 211(5): 885-894, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37486211
3.
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and ß-Thalassemia.
N Engl J Med
; 384(3): 252-260, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33283989
4.
First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
Br J Haematol
; 201(5): 913-916, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36896578
5.
Psychiatric comorbidities in adults with sickle cell disease: A narrative review.
Br J Haematol
; 203(5): 747-759, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37455514
6.
Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.
Blood
; 137(13): 1754-1764, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33036022
7.
Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients.
Eur J Haematol
; 111(3): 499-505, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37365676
8.
Development of T-cell immunity in a liver and hematopoietic stem cell transplant recipient following coronavirus disease 2019 infection.
Cytotherapy
; 23(11): 980-984, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34183244
9.
Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
Transpl Infect Dis
; 23(2): e13487, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33034124
10.
Fertility Concerns and Access to Care for Stem Cell Transplantation Candidates with Sickle Cell Disease.
Biol Blood Marrow Transplant
; 26(8): e192-e197, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315707
11.
Standardized Semi-structured Psychosocial Evaluation before Hematopoietic Stem Cell Transplantation Predicts Patient Adherence to Post-Transplant Regimen.
Biol Blood Marrow Transplant
; 25(11): 2222-2227, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31247314
12.
Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.
Haematologica
; 103(10): 1688-1697, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29954930
13.
CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.
Am J Hematol
; 93(6): 786-793, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603337
14.
Impact of bone marrow minimal residual disease status on quality of organ response in systemic AL amyloidosis.
Am J Hematol
; 97(7): E244-E246, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385144
15.
Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.
J Am Soc Nephrol
; 27(7): 1911-5, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27147425
16.
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.
Am J Hematol
; 95(9): E239-E242, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32401372
17.
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Lancet Oncol
; 15(1): 87-95, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295572
18.
IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.
Biol Blood Marrow Transplant
; 20(2): 192-201, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24239650
19.
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.
Blood
; 119(22): 5088-103, 2012 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22403259
20.
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Blood
; 119(20): 4608-13, 2012 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22451423